Tvardi Therapeutics (NASDAQ:TVRD) Price Target Cut to $15.00 by Analysts at BTIG Research

Key Points

• Tvardi Therapeutics' price target has been significantly reduced by BTIG Research from $55.00 to $15.00, but the firm maintains a "buy" rating despite the downgrade.
• The stock experienced a dramatic drop of 84.4% in trading, closing at just $6.49, amid ongoing analyst revisions and negative earnings reports.
• Institutional ownership is relatively strong, with 44.66% of the stock held by institutional investors and hedge funds as they modify their positions during the company's financial downturn.

Tvardi Therapeutics (NASDAQ:TVRD - Get Free Report) had its price target dropped by stock analysts at BTIG Research from $55.00 to $15.00 in a research note issued to investors on Monday,Benzinga reports. The brokerage presently has a "buy" rating on the stock. BTIG Research's target price points to a potential upside of 131.12% from the stock's previous close.

A number of other research analysts have also issued reports on TVRD. Piper Sandler lowered shares of Tvardi Therapeutics from an "overweight" rating to a "neutral" rating in a research note on Monday. Raymond James Financial assumed coverage on Tvardi Therapeutics in a research report on Monday, July 14th. They set an "outperform" rating and a $62.00 target price on the stock. Weiss Ratings reaffirmed a "sell (e)" rating on shares of Tvardi Therapeutics in a report on Saturday, September 27th. Cantor Fitzgerald lowered Tvardi Therapeutics from an "overweight" rating to a "neutral" rating in a report on Monday. Finally, Barclays initiated coverage on Tvardi Therapeutics in a report on Monday. They set an "overweight" rating and a $61.00 price objective on the stock. Four research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company's stock. Based on data from MarketBeat.com, Tvardi Therapeutics has an average rating of "Hold" and a consensus target price of $55.50.

Tvardi Therapeutics Trading Down 84.4%

Shares of NASDAQ:TVRD traded down $35.11 during trading on Monday, reaching $6.49. The company had a trading volume of 4,390,539 shares, compared to its average volume of 57,278. The firm's fifty day moving average price is $32.02. Tvardi Therapeutics has a fifty-two week low of $5.65 and a fifty-two week high of $43.65.

Tvardi Therapeutics (NASDAQ:TVRD - Get Free Report) last announced its quarterly earnings data on Thursday, August 14th. The company reported ($1.00) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.51) by ($0.49). Tvardi Therapeutics had a negative net margin of 678.79% and a negative return on equity of 565.83%.

Institutional Trading of Tvardi Therapeutics

Several large investors have recently modified their holdings of TVRD. JPMorgan Chase & Co. acquired a new stake in shares of Tvardi Therapeutics in the second quarter valued at approximately $39,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. acquired a new stake in Tvardi Therapeutics during the 2nd quarter valued at $43,000. Headlands Technologies LLC acquired a new stake in Tvardi Therapeutics during the 2nd quarter valued at $80,000. New York State Common Retirement Fund acquired a new stake in shares of Tvardi Therapeutics during the second quarter valued at $92,000. Finally, Bank of America Corp DE acquired a new stake in shares of Tvardi Therapeutics during the second quarter valued at $399,000. 44.66% of the stock is currently owned by institutional investors and hedge funds.

Tvardi Therapeutics Company Profile

Cara Therapeutics, Inc, an early commercial-stage biopharmaceutical company, focuses on developing and commercializing chemical entities with a primary focus on pruritus and pain by selectively targeting kappa opioid receptors in the United States. The company is developing product candidates that target the body's peripheral nervous system and immune cells.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.